<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01352559</url>
  </required_header>
  <id_info>
    <org_study_id>2001-11-03</org_study_id>
    <nct_id>NCT01352559</nct_id>
  </id_info>
  <brief_title>Prediction of Antidepressant Response Using Pharmacogenetics and Peripheral Lymphocytic Phenotype</brief_title>
  <official_title>Prediction of Antidepressant Response Using Pharmacogenetics of Bioamine Transporter and Peripheral Lymphocytic Phenotype</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether pharmacogenomic study of bioamine
      transporters and peripheral lymphatic biomarkers(phenotype) predict antidepressant
      responsiveness in advance before the appearance of the drug effects until 4~6 weeks after
      drug administration.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to determine whether genomic effects or peripheral lymphatic
      biomarkers on antidepressant response differed by class of drug, whether genomic and
      biomarker differences between drug responders and nonresponders predict the response of
      antidepressant and to construct the prediction model for antidepressant treatment in order to
      aid to select the their genetically or endophenotypic matching drugs.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>November 2001</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Actual">March 2007</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Antidepressant Response at 6 weeks</measure>
    <time_frame>6 weeks</time_frame>
    <description>antidepressant response is defined as the decrease rate of HAM-D score for 6week was = or &gt; 50%
Measurement Unit = responders, nonresponders</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biological value at 0 and 6 weeks</measure>
    <time_frame>6 weeks</time_frame>
    <description>Biological value is defined as
Genetic information of bioamine transporter genes of patients. Measurement unit = if it is SNP,it is A, T, G, or C, and if VNTR, short or long allele
or
Biological measure value of patients at 0 and 6week after antidepressant treatment(ex. peripheral markers such as serum BDNF, CREB...).
Measurement unit = numerical value and thier unit such as O.D.(Optical Density)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>responders</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 â‰¤ Decrease rate(%) of HAM-D score</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non-responders</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>nonresponders is a patients having 50 &gt; Decrease rate(%) of HAM-D score</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>responders</intervention_name>
    <description>Antidepressants administration for 6 weeks under therapeutic dose</description>
    <arm_group_label>responders</arm_group_label>
    <other_name>fluoxetine_Prozac</other_name>
    <other_name>paroxetine_Paxil, Seroxat</other_name>
    <other_name>sertraline_Zoloft</other_name>
    <other_name>milnacipran</other_name>
    <other_name>venlafaxine_Effexor</other_name>
    <other_name>nortriptyline_Aventyl, Pamelor, Noritren</other_name>
    <other_name>mirtazapine_Avanza, Zispin, Remeron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>non-responders</intervention_name>
    <description>Antidepressants administration for 6 weeks under therapeutic dose</description>
    <arm_group_label>non-responders</arm_group_label>
    <other_name>SSRI nonresponders</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. eligible patients were enrolled in the clinical trials program of hte Samsung Medical
             Center Geropsychiatry and Affective Disorder Clinics(Seoul, Korea). They received a
             semistructured diagnostic interview, the Samsung Psychiatric Evaluation Schedule. The
             affective disorder section of the Samsung Psychiatric Evaluation Schedule uses the
             Korean version of the structured clinical interview for the diagnostic and statistical
             manual of mental disorders, Fourth edition.

          2. interview with one more patient's family member for objective diagnosis and final
             diagnosis decision by agreements of two more psychiatric physicians

        Exclusion Criteria:

          1. received psychotropic medication within 2 weeks of the study or fluoxetine within 4
             weeks

          2. potential study participants for pregnancy, significant medical conditions, abnormal
             laboratory baseline values, unstable psychiatric features(eg.suicidal), history of
             alcohol of drug dependence, seizures, head trauma with loss of consciousness,
             neurological illness, or concomitant Axis I psychiatric disorder.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Doh Kwan Kim, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Kangnam</city>
        <state>Seoul</state>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 21, 2011</study_first_submitted>
  <study_first_submitted_qc>May 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2011</study_first_posted>
  <last_update_submitted>December 30, 2015</last_update_submitted>
  <last_update_submitted_qc>December 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 31, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Doh Kwan Kim</investigator_full_name>
    <investigator_title>M.D., pHD</investigator_title>
  </responsible_party>
  <keyword>Pharmacogenomics</keyword>
  <keyword>Prediction of Antidepressant Response</keyword>
  <keyword>Depressed Patients</keyword>
  <keyword>biomarkers</keyword>
  <keyword>phenotype</keyword>
  <keyword>Antidepressant Response</keyword>
  <keyword>Adverse Reaction to Drug</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antidepressive Agents</mesh_term>
    <mesh_term>Nortriptyline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

